FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma

FTL004, an anti-CD38 mAb with negligible RBC binding and enhanced pro-apoptotic activity, is a novel candidate for treatments of multiple myeloma and non-Hodgkin lymphoma

Abstract Anti-CD38 monoclonal antibodies (mAbs), daratumumab, and isatuximab have represented a breakthrough in the treatment of multiple myeloma (MM). Recently, CD38-based mAbs were expected to achieve increasing potential beyond MM, which encouraged us to develop new anti-CD38 mAbs to meet clinica...

Full description

Bibliographic Details
Main Authors: Guangbing Zhang, Cuiyu Guo, Yan Wang, Xianda Zhang, Shuang Liu, Wen Qu, Chunxia Chen, Lingli Yan, Zhouning Yang, Zhixiong Zhang, Xiaohua Jiang, Xiaofeng Chen, Hong Liu, Qinhuai Lai, Xian Wei, Ying Lu, Shengyan Zhao, Han Deng, Yuxi Wang, Lin Yu, Hongbin Yu, Yu Wu, Zhaoming Su, Pengyu Chen, Ziqing Ren, Meng Yu, Feng Qu, Yong Luo, Lantu Gou, Qing Li, Ying Huang, Fanxin Ma, Jinliang Yang
Format: Article
Language:English
Published: BMC 2022-12-01
Series:Journal of Hematology & Oncology
Subjects:
Multiple myeloma
Monoclonal antibodies
CD38
Red blood cells
Direct apoptosis
Online Access:https://doi.org/10.1186/s13045-022-01395-0

Similar Items

Similar Items